[Magnesium Isoglycyrrhizinate in the Treatment of Chronic Liver Diseases: a Randomized, Double-Blind, Multi-Doses, Active Drug Controlled, Multi-Center Study].
Yi-min Mao,Min-de Zeng,Yong Chen,Cheng-wei Chen,Qing-chun Fu,Xiong Cai,Shan-ming Wu,Ya-gang Chen,Ying Sun,Jun Li,Yan-hua Sui,Wei Zhao,Lun-gen Lu,Ai-ping Cao,Hong-zhuan Chen
DOI: https://doi.org/10.3760/cma.j.issn.1007-3418.2009.11.013
2009-01-01
Abstract:OBJECTIVE:To evaluate the efficacy and safety of Magnesium isoglycyrrhizinate in treatment of chronic liver diseases. METHODS:It is a randomized, double-blind, multi-doses, active drug controlled, multi-center study. 480 proper patients were randomly divided into group A (180 patients), group B (180 patients) or group C (120 patients). Patients in group A received magnesium isoglycyrrhizinate 100 mg once daily. Patients in group B received magnesium isoglycyrrhizinate 150 mg once daily. Patients in group C received compound glycyrrhizin 120 mg once daily. The treatment course was 4 weeks. Patients were followed up 2 weeks after the treatment. Patients visited once every 2 weeks. Clinical symptoms, ALT, AST were evaluated in all the patients before treatment, at week 2, at week 4 and at 2 weeks later after treatment. The other liver function test was done before treatment and at week 4. RESULTS:412 patients completed the study according to the protocol,152 in group A, 160 in group B and 100 in group C. ALT and AST level were significantly decreased in all groups at week 2 and week 4 (P < 0.05). The degree of ALT decrease is greater in group B than in group C at week 2 (P < 0.01). The degree of ALT decrease was not significant different among three groups at week 4 (P > 0.05). The rates of ALT improvement at week 4 in group A, B, C were 92.59%, 91.76%, 88.29%, respectively (P > 0.05). The rates of symptoms improvement at week 4 in group A, B, C were 90.41%, 89.86%, 86.46% and 72.22%, 73.53%, 68.47%, respectively (P > 0.05). No relapse were found in all three groups after treatment. The rate of adverse event in three groups was similar (P > 0.05). CONCLUSION:Magnesium isoglycyrrhizinate is an effective and safe treatment for chronic liver diseases.